Gilead wins US approval for Yeztugo HIV prevention shot, but its $28,000 price sparks access concerns despite near-perfect ...

JPMorgan (NYSE: JPM) told investors in a note Monday that Eli Lilly & Co. (NYSE: LLY) shares are its “top pick” among U.S.

The Galien Foundation, the premier global institution dedicated to honoring innovators in life sciences, today ...

Even though oncology segment revenue inched up just 1 percent year over year, the firm lifted full-year expectations slightly ...

Analysts lift targets for Gilead as HIV sales surge and Yeztugo launch gains traction, supporting a stronger full-year ...

Gilead stock briefly broke out Friday after the biotech company beat second-quarter forecasts amid its newest launch in HIV ...

Gilead's PrEP Yeztugo is set to become the pharma's star asset, with GlobalData forecasting of just under $5bn in 2031.

After the recent approval and launch of twice-yearly HIV prophylactic Yeztugo, Gilead Sciences is cleaning up its R&D pipeline. | After the recent approval and launch of twice-yearly HIV prophylactic ...

Gilead Sciences (NASDAQ:GILD) announced its second-quarter 2025 earnings and revised annual outlook after the market closed ...

Quarterly revenue from Yescarta came in at $393 million, which was a 5% decline from the second quarter of last year, while Tecartus saw a 14% drop-off to $92 million. In both cases, Gilead explained ...

Kenya is one of nine African countries selected for the initial rollout of lenacapavir (LEN), a new injectable drug for human ...